当前位置: 首页 >> 检索结果
2841. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study.
作者: M Cushman.;C Legault.;E Barrett-Connor.;M L Stefanick.;C Kessler.;H L Judd.;P A Sakkinen.;R P Tracy.
来源: Circulation. 1999年100卷7期717-22页
Observational studies in healthy women suggest postmenopausal hormone therapy reduces risk of coronary events. In contrast, in a recent clinical trial of women with coronary disease, a subgroup analysis demonstrated increased risk during the early months of therapy. Because higher levels of inflammation factors predict vascular disease outcomes, the effect of hormones on these factors is of interest.
2842. Developmental and neurological status of children at 4 years of age after heart surgery with hypothermic circulatory arrest or low-flow cardiopulmonary bypass.
作者: D C Bellinger.;D Wypij.;K C Kuban.;L A Rappaport.;P R Hickey.;G Wernovsky.;R A Jonas.;J W Newburger.
来源: Circulation. 1999年100卷5期526-32页
It is not known whether developmental and neurological outcomes in the preschool period differ depending on whether the predominant vital organ support strategy used in infant heart surgery was total circulatory arrest (CA) or low-flow cardiopulmonary bypass.
2843. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction.
Studies have suggested that ACE inhibitors have an antiarrhythmic effect on ventricular arrhythmias. Whether they have an effect on atrial fibrillation is unknown.
2844. Efficacy and safety of ibutilide fumarate for the conversion of atrial arrhythmias after cardiac surgery.
作者: J T VanderLugt.;T Mattioni.;S Denker.;D Torchiana.;T Ahern.;L K Wakefield.;K T Perry.;P R Kowey.
来源: Circulation. 1999年100卷4期369-75页
Atrial arrhythmias occur commonly after cardiac surgery and are a cause of significant morbidity and increased hospital costs, yet there is no well-studied treatment strategy to deal with them expeditiously. The purpose of this study was to determine the efficacy and safety of ibutilide fumarate, an approved drug for the rapid conversion of atrial fibrillation and flutter, in patients after cardiac surgery.
2845. Effects of oral folic acid supplementation on endothelial function in familial hypercholesterolemia. A randomized placebo-controlled trial.
作者: M C Verhaar.;R M Wever.;J J Kastelein.;D van Loon.;S Milstien.;H A Koomans.;T J Rabelink.
来源: Circulation. 1999年100卷4期335-8页
Folates have been suggested to be of benefit in reducing cardiovascular risk. The present study was designed to examine whether oral folic acid supplementation could improve endothelial function as an intermediate end point for cardiovascular risk in patients with increased risk of atherosclerosis due to familial hypercholesterolemia (FH).
2846. Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analyses. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group.
作者: R P Byington.;G W Evans.;M A Espeland.;W B Applegate.;D B Hunninghake.;J Probstfield.;C D Furberg.
来源: Circulation. 1999年100卷3期e14-7页
Few clinical trials have documented the efficacy of preventive treatment in asymptomatic women.
2847. Role of bradykinin in the vasodilator effects of losartan and enalapril in patients with heart failure.
ACE inhibitors have been shown to potentiate the effects of exogenous bradykinin by inhibition of its breakdown. Despite this, there is little evidence that inhibition of endogenous bradykinin breakdown actually contributes to the effects of ACE inhibitors, or indeed, other inhibitors of the renin-angiotensin system, such as angiotensin II type I receptor (AT(1)) antagonists, and no evidence at all that it does so in patients with heart failure.
2848. Primary stenting versus balloon angioplasty in occluded coronary arteries: the Total Occlusion Study of Canada (TOSCA).
作者: C E Buller.;V Dzavik.;R G Carere.;G B Mancini.;G Barbeau.;C Lazzam.;T J Anderson.;M L Knudtson.;J F Marquis.;T Suzuki.;E A Cohen.;R S Fox.;K K Teo.
来源: Circulation. 1999年100卷3期236-42页
Balloon angioplasty (PTCA) of occluded coronary arteries is limited by high rates of restenosis and reocclusion. Although stenting improves results in anatomically simple occlusions, its effect on patency and clinical outcome in a broadly selected population with occluded coronary arteries is unknown.
2849. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators.
Elevated plasma concentrations of C-reactive protein (CRP) are associated with increased cardiovascular risk. We evaluated whether long-term therapy with pravastatin, an agent that reduces cardiovascular risk, might alter levels of this inflammatory parameter.
2850. Increased incidence of periprocedural complications among patients with peripheral vascular disease undergoing myocardial revascularization in the bypass angioplasty revascularization investigation.
作者: C S Rihal.;K Sutton-Tyrrell.;P Guo.;N M Keller.;R Jandova.;M A Sellers.;H V Schaff.;D R Holmes.
来源: Circulation. 1999年100卷2期171-7页
Risks of coronary artery bypass graft surgery (CABG) or percutaneous transluminal coronary angioplasty (PTCA) may be different in the presence of peripheral vascular disease (PVD).
2851. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study.
作者: H A Valantine.;S Z Gao.;S G Menon.;D G Renlund.;S A Hunt.;P Oyer.;E B Stinson.;B W Brown.;T C Merigan.;J S Schroeder.
来源: Circulation. 1999年100卷1期61-6页
Coronary artery disease occurs in an accelerated fashion in the donor heart after heart transplantation (TxCAD), but the cause is poorly understood. The risk of developing TxCAD is increased by cytomegalovirus (CMV) infection and decreased by use of calcium blockers. Our group observed that prophylactic administration of ganciclovir early after heart transplantation inhibited CMV illness, and we now propose to determine whether this therapy also prevents TxCAD.
2852. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty.
作者: E Tsuchikane.;A Fukuhara.;T Kobayashi.;M Kirino.;K Yamasaki.;T Kobayashi.;M Izumi.;S Otsuji.;H Tateyama.;M Sakurai.;N Awata.
来源: Circulation. 1999年100卷1期21-6页
Restenosis after percutaneous transluminal coronary (balloon) angioplasty (PTCA) remains a major drawback of the procedure. We previously reported that cilostazol, a platelet aggregation inhibitor, inhibited intimal proliferation after directional coronary atherectomy and reduced the restenosis rate in humans. The present study aimed to determine the effect of cilostazol on restenosis after PTCA.
2853. Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial.
作者: P B Berger.;S G Ellis.;D R Holmes.;C B Granger.;D A Criger.;A Betriu.;E J Topol.;R M Califf.
来源: Circulation. 1999年100卷1期14-20页
Time to treatment with thrombolytic therapy is a critical determinant of mortality in acute myocardial infarction. Little is known about the relationship between the time to treatment with direct coronary angioplasty and clinical outcome. The objectives of this study were to determine both the time required to perform direct coronary angioplasty in the Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes (GUSTO-IIb) trial and its relationship to clinical outcome.
2854. Five-year outcome in patients with isolated proximal left anterior descending coronary artery stenosis treated by angioplasty or left internal mammary artery grafting. A prospective trial.
作者: J J Goy.;E Eeckhout.;C Moret.;B Burnand.;P Vogt.;J C Stauffer.;M Hurni.;F Stumpe.;P Ruchat.;L von Segesser.;P Urban.;L Kappenberger.
来源: Circulation. 1999年99卷25期3255-9页
Percutaneous transluminal coronary angioplasty (PTCA) and coronary artery bypass surgery (CABG) improve the clinical status of patients with isolated proximal left anterior descending coronary artery stenosis. At 2 years, only additional revascularization was more frequently required after PTCA.
2855. Long-term ascorbic acid administration reverses endothelial vasomotor dysfunction in patients with coronary artery disease.
作者: N Gokce.;J F Keaney.;B Frei.;M Holbrook.;M Olesiak.;B J Zachariah.;C Leeuwenburgh.;J W Heinecke.;J A Vita.
来源: Circulation. 1999年99卷25期3234-40页
Loss of endothelium-derived nitric oxide (EDNO) contributes to the clinical expression of coronary artery disease (CAD). Increased oxidative stress has been linked to impaired endothelial vasomotor function in atherosclerosis, and recent studies demonstrated that short-term ascorbic acid treatment improves endothelial function.
2856. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial.
Cholesterol lowering reduces coronary events. One mechanism could be improvement of endothelial function. In line with this hypothesis, this study investigates whether cholesterol reduction can result in rapid improvement of endothelial function after acute coronary syndromes.
2857. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure.
作者: A Deswal.;B Bozkurt.;Y Seta.;S Parilti-Eiswirth.;F A Hayes.;C Blosch.;D L Mann.
来源: Circulation. 1999年99卷25期3224-6页
Although previous studies suggested that TNF may contribute to heart failure progression, it is unclear whether antagonizing TNF is beneficial in heart failure patients.
2858. Health-related quality of life after angioplasty and stent placement in patients with iliac artery occlusive disease: results of a randomized controlled clinical trial. The Dutch Iliac Stent Trial Study Group.
To assess the quality of life in patients with iliac artery occlusive disease, we compared primary stent placement versus primary angioplasty followed by selective stent placement in a multicenter randomized controlled trial.
2859. Effect of pacing chamber and atrioventricular delay on acute systolic function of paced patients with congestive heart failure. The Pacing Therapies for Congestive Heart Failure Study Group. The Guidant Congestive Heart Failure Research Group.
作者: A Auricchio.;C Stellbrink.;M Block.;S Sack.;J Vogt.;P Bakker.;H Klein.;A Kramer.;J Ding.;R Salo.;B Tockman.;T Pochet.;J Spinelli.
来源: Circulation. 1999年99卷23期2993-3001页
Previous studies of pacing therapy for dilated congestive heart failure (CHF) have not established the relative importance of pacing site, AV delay, and patient heterogeneity on outcome. These variables were compared by a novel technique that evaluated immediate changes in hemodynamic function during brief periods of atrial-synchronous ventricular pacing.
2860. Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure.
Angiotensin converting enzyme (ACE) inhibition after myocardial infarction is associated with an improvement in plasma fibrinolytic parameters. The aim of the present study was to determine whether acute ACE inhibition and angiotensin II type 1 (AT1) receptor antagonism have similar effects in patients with heart failure.
|